Verrica Pharmaceuticals Inc. Q3 2026 Earnings Call Summary
Verrica (VRCA) Q3 2026 Earnings Call Transcript
Verrica Pharmaceuticals Q3 Earnings Call Highlights
Verrica Pharmaceuticals Reports Third Quarter 2026 Financial Results
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London
Verrica Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026
Verrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit Facility
Verrica Pharmaceuticals Q2 2026 Earnings Call Transcript
Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences
Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Verrica completes enrolment in Phase III trial of Ycanth
Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027
Verrica Pharmaceuticals Q2 Earnings Call Highlights
Verrica Pharmaceuticals Inc. (VRCA) Q2 2026 Earnings Call Transcript
Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Beats Revenue Estimates
Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results
Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital
Verrica Pharmaceuticals Q2 Adj. EPS $(0.48) Misses $(0.38) Estimate, Sales $5.862M Beat $5.733M Estimate
Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.